Cost Analysis of Clinical Compounding in Saudi Arabia: Antihypertensive of Pediatric Formulations

Yousef Ahmed Alomi; Fatimah Fouad Al Doughan; Faiz A. Bahadig; Malika Alhadab; Mona Lubbad; Ebtesam Nazal

Abstract

International Journal of Pharmacology and Clinical Sciences,2019,8,3s,s2-s6.

DOI:10.5530/ijpcs.2019.8.36

Published:November 2019

Type:Research Article

Authors:

Author(s) affiliations:

Yousef Ahmed Alomi*, General Administration of Pharmaceutical Care, Ministry of Health, Riyadh, Saudi Arabia. Fatimah Fouad Al Doughan, Pharmacy Practice department, College of Clinical Pharmacy, King Faisal University, Alahsaa, SAUDI ARABIA.

Faiz A. Bahadig, Informatics Pharmacist, Pharmaceutical Care Department, King Abdul-Aziz Medical, City-WRJeddah, Ministry of National Guard, SAUDI ARABIA.

Malika Alhadab, Head, Pharmacy Services, Alyamma Hopsital, Ministry of Health, Riyadh, SAUDI ARABIA.

Mona Lubbad, Former Head, Extemporaneous Preparation Unit, Pharmacy services, Alyamma Hopsital, Ministry of Health, Riyadh, SAUDI ARABIA.

Ebtesam Nazal, Head, Extemporaneous Preparation Unit, Pharmacy Services, Alyamma Hopsital, Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract:

Objectives: The primary objective of this study was to explore cost analysis of pediatric formulations in Riyadh city, Saudi Arabia. Methods: This is a retrospective study of cost analysis of pediatric formulations at 300-bed pediatric and maternity hospital in Riyadh city, Saudi Arabia. The pharmacy section of this hospital receives the specific formulation from the physician. Then, the expert pharmacist applied the international standard for clinical compounding and provides services to the healthcare staff and patients over 8 hr per day for 5 days per week. The pediatric formulations consisted of but not limited to antibiotics, anti-tuberculosis (TB) medications and anti-hypertensive medications. The cost analysis included the variable expenses such as personal cost, material cost and supply cost and fixed expenses such as direct cost, non-salary cost and overhead cost. The cost was derived from the Ministry of Health information database. All costs used have been analyzed in US dollar currency. In this study, we analyzed the cost of antihypertensive medications for pediatric use through the Microsoft Excel software (version 10). Results: The estimated average total standard cost of pediatric formulations per hour was 53.82 USD and consisted of 58.58% (31.53 USD) for personal cost, 25.14% (13.53 USD) for overhead cost, 3.34% (1.8 USD) for material and supply cost and 12.93% (6.96 USD) for the non-salary cost. The average estimated cost of Propranolol, Captopril, Methyldopa, Amlodipine and Hydralazine per each preparation was (8.27 USD, 2.37 USD, 6.88 USD, 17.385 USD) and (49.44 USD), respectively. Conclusion: To the best of our knowledge, this is the first study which demonstrated the cost analysis of antihypertensive pediatric formulation in the Kingdom of Saudi Arabia. The pediatric formulations with cost analysis can involve health insurance coverage. Targeting the cost analysis of all pediatric formulation is highly recommended to fit with Saudi vision 2030 in the Kingdom of Saudi Arabia.